C. Cheng

发表

Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse

S. Raimondi, C. Pui, R. Ribeiro, 2004, Leukemia.

Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells

J. Downing, M. Relling, C. Pui, 2003, Nature Genetics.

Comparison of Native E. coli and PEG Asparaginase Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia

W. Liu, M. Relling, J. Panetta, 2009, Clinical pharmacology and therapeutics.

Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia

M. Relling, C. Pui, D. Pei, 2004, Leukemia.

A Revised Definition for Cure of Childhood Acute Lymphoblastic Leukemia

J. Downing, S. Raimondi, M. Relling, 2014, Leukemia.

Genome-wide approach to identify risk factors for therapy-related myeloid leukemia

M. Relling, C. Pui, A. Bogni, 2006, Leukemia.

Long-term results of St. Jude Total Therapy studies 11, 12, 13A, 13B and 14 for childhood acute lymphoblastic leukemia

J. Downing, D. Campana, C. Pui, 2009, Leukemia.

Preview : Published ahead of advance online publication The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies

M. Sekeres, M. Kalaycio, T. Radivoyevitch, 2016 .

VPREB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia

C. Pui, C. Mullighan, S. Hunger, 2014, Leukemia.

Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation

P. Boffetta, R. Ribeiro, G. Zambetti, 2005, Journal of Medical Genetics.

Genetic Polymorphism of Inosine Triphosphate Pyrophosphatase Is a Determinant of Mercaptopurine Metabolism and Toxicity During Treatment for Acute Lymphoblastic Leukemia

M. Relling, C. Pui, W. Evans, 2009, Clinical pharmacology and therapeutics.

Biomarker Discovery: Identification of a Growth Factor Gene Signature

H. Dai, A. Loboda, A. Loboda, 2009, Clinical pharmacology and therapeutics.

ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy

S. Shurtleff, S. Raimondi, M. Relling, 2012, Leukemia.

Etoposide Sensitivity Does Not Predict MLL Rearrangements or Risk of Therapy‐Related Acute Myeloid Leukemia

M. Relling, Jun J. Yang, A. Bogni, 2008, Clinical pharmacology and therapeutics.